Keros Therapeutics (NASDAQ:KROS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Keros Therapeutics (NASDAQ:KROS) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $40.00 price target on the stock.

A number of other research analysts also recently issued reports on the stock. Oppenheimer decreased their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday, January 16th. Truist Financial decreased their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Piper Sandler decreased their price target on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Trading Down 6.3 %

Keros Therapeutics stock opened at $9.55 on Tuesday. The firm has a market capitalization of $387.37 million, a P/E ratio of -1.83 and a beta of 1.39. Keros Therapeutics has a twelve month low of $9.41 and a twelve month high of $72.37. The stock’s fifty day simple moving average is $11.10 and its 200-day simple moving average is $33.64.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Sell-side analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KROS. MetLife Investment Management LLC boosted its holdings in shares of Keros Therapeutics by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company’s stock valued at $286,000 after acquiring an additional 1,027 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its position in Keros Therapeutics by 36.7% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after purchasing an additional 1,033 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in Keros Therapeutics by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after purchasing an additional 1,100 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after purchasing an additional 1,372 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Keros Therapeutics by 7.8% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,184 shares of the company’s stock valued at $303,000 after purchasing an additional 1,386 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.